Results for tag: "Recombinant Human Parathyroid Hormone"

The Recombinant Human Parathyroid Hormone (rhPTH) market is a segment of the Endocrine and Metabolic Disorders Drugs market. rhPTH is a synthetic version of the naturally occurring hormone, parathyroid hormone, which is responsible for regulating calcium and phosphorus levels in the body. It is used to treat osteoporosis, a condition characterized by low bone mineral density, in postmenopausal women and men with osteoporosis. rhPTH is also used to treat hypoparathyroidism, a condition in which the body does not produce enough parathyroid hormone. The rhPTH market is expected to grow due to the increasing prevalence of osteoporosis and hypoparathyroidism, as well as the increasing demand for rhPTH drugs. The market is also driven by the increasing availability of rhPTH drugs, as well as the increasing awareness of the importance of bone health. Some companies in the rhPTH market include Amgen, Eli Lilly, Novartis, and Pfizer. Show Less Read more